A PBS listing appears unlikely for fulvestrant for women with hormone receptor positive metastatic breast cancer because of disagreement over pricing, a patient advocacy group says. The selective oestrogen receptor down‐regulator (SERD) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) to be used in combination with CDK4/6 inhibitor drugs but Breast ...
Fulvestrant won’t be PBS listed for women with HR+ breast cancer
By Michael Woodhead
19 Nov 2020